WuXi AppTec : 2022 J.P. Morgan Presentation

WuXi AppTec

2022 J . P. Morgan Healthcare Conference

January 10, 2022

1	603259.SH / 2359.HK

"Forward-Looking Statements

This presentation may contain certain "forward-looking statements" which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, our ability to protect our clients' intellectual property, unforeseeable international tension, competition, the impact of emergencies and other force majeure. Our forward-looking statements in this presentation speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this presentation is as of the date of this presentation and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement, except as required under applicable law.

	Non-IFRS Financial Measures
	We provide Non-IFRS gross profit and Non-IFRS net profit attributable to owners of the Company, which exclude share-based compensation expenses, listing expenses and
	issuance expenses of convertible bonds, fair value gain or loss from derivative component of convertible bonds, foreign exchange-related gains or losses and amortization of
	intangible assets acquired in business combinations and goodwill impairment. We also provide adjusted Non-IFRS net profit attributable to owners of the Company and
	earnings per share, which further exclude realized and unrealized gains or losses from our venture investments and joint ventures. We further provide EBITDA and adjusted
	EBITDA. Neither of above is required by, or presented in accordance with IFRS. Meanwhile, to better reflect the operation results and key performance, the Company has
	adjusted the scope of the foreign exchange-related gains or losses by excluding only the gains or losses that we believe irrelevant to the core business. The comparative
	financial figures for the comparable periods have been adjusted to reflect the change of the scope.
	We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing our core business performance and operating trends,
	and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the
	impact of certain unusual, non-recurring,non-cash and non-operating items that we do not consider indicative of the performance of our core business. Such Non-IFRS
	financial measures, the management of the Company believes, is widely accepted and adopted in the industry the Company is operating in. However, the presentation of
	these adjusted Non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in
	accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or
	forecasted by other companies.
	Disclaimer
	All intellectual property rights and other rights pertaining to the information and materials presented in the results briefing are owned by WuXi AppTec Co., Ltd. ("WuXi
	AppTec" or the "Company"). Audio recording, video recording or disclosure of such materials by any means without the prior consent of WuXi AppTec is prohibited. This
2	briefing does not intend to provide a complete statement of the relevant matters. For relevant information, please refer to the 2021 third quarterly report published on the

website of Hong Kong Stock Exchange (www.hkexnews.hk).

01 Company Overview

02 Business Highlights

03 Financial Performance

04 Growth Outlook

Notes:

All financials disclosed in this presentation are prepared based on International Financial Reporting Standards (or "IFRSs"). The unit of currency is RMB.

3

1. Company Overview

4

Integrated, End-to-End CRDMO & CTDMO Enabling Platform

Our open-access capabilities and technology platforms deliver quality service - and help global customers and partners achieve their goals more quickly - by lowering the cost of research and development and shortening the time required to discover and produce new medicines.

WuXi Chemistry WuXi Biology

WuXi Testing

WuXi ATU

WuXi DDSU

Manufacturing
Research	Clinical Trials
Development	Testing

5

5